Metsera expects its cash will last into 2027. Two other life science companies went public this past week. Here’s a look at those IPOs: Maze Therapeutics Finds Way to $140M IPO for Chronic ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

A week after the first IPO of the year was priced, obesity treatment developer Metsera Inc. and renal specialist Maze Therapeutics Inc. have begun trading on Nasdaq. Metsera (NASDAQ:MTSR) surged 47% ...

Its prospectus says that the IPO will fund phase 1 and phase ... in the footsteps of obesity drug developer Metsera and genetic medicines developer Maze Therapeutics, which filed to list on ...

Metsera’s (NASDAQ:MTSR – Get Free Report) quiet period is set to expire on Wednesday, March 12th. Metsera had issued 15,277,778 shares in its initial public offering on January 31st. The total size of ...

Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...

The newly listed clinical-stage biotechnology company, Metsera Inc. rose 15.01% on Monday as the broader markets declined.

Metsera Inc. MTSR, a New York-based biotech that went public on Jan. 31 with some fanfare, has a full portfolio of weight-loss drugs in development, using both the hormones already used in ...

Guggenheim initiated coverage of Metsera (MTSR) with a Buy rating and $56 price target The firm sees a “highly promising multi-billion ...

Guggenheim has initiated Metsera at buy saying that the biotech's pipeline of injectable and oral nutrient stimulated hormone (NuSH) analog peptides to treat obesity could be "a multibillion ...

Maze Therapeutics’ (NASDAQ:MAZE – Get Free Report) quiet period will expire on Wednesday, March 12th. Maze Therapeutics had issued 8,750,000 shares in its initial public offering on January 31st. The ...